A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM). Bisphosphonates such as zoledronic acid (ZLD) reduce skeletal events in MM and the immunomodulatory agent thalidomide (Thal) has proven effectiveness in active MM. We hy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Witzig, TE, Laumann, KM, Lacy, MQ, Hayman, SR, Dispenzieri, A, Kumar, S, Reeder, CB, Roy, V, Lust, JA, Gertz, MA, Greipp, PR, Hassoun, H, Mandrekar, SJ, Rajkumar, SV
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2012
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3912579/
https://ncbi.nlm.nih.gov/pubmed/22902362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.236
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge